• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melinda Magyari Explores What Registries Reveal About Pediatric MS

Video

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Melinda Magyari, MD, PhD, Consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explores what data registry have shown about factors that are linked with secondary progression in pediatric multiple sclerosis (MS).

Transcript

Have registry data revealed any factors related to secondary progression in pediatric MS?

The definition of secondary progression, it's very difficult. So you need to use a composite definition as a proxy. And that's a really hot topic, how to do that composite definition. Also because clinicians are reluctant to define the disease progression because there is no current treatment for secondary progressive MS. However, you see in 2 big, good registries that children progress slowly, but they reach secondary progression phase at a younger age, so 10 years younger than adults.

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
Kimberly Westrich, MA, chief strategy officer, NPC
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.